View Post

Caris Life Sciences Study Provides First Systematic Assessment of RNA Expression of Key Molecules Involved in the Infectious Process Leading to COVID-19 in Advanced Cancer

In Clinical Studies News by Barbara Jacoby

Source: Caris Life Sciences From: PR Newswire New Data Published in Scientific Reports Reveals Possible Biological Underpinnings of Cancer Patients Hyper-Immune Response to COVID-19 Infection Patients with cancer demonstrate particularly poor outcomes from COVID-19. Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, has published results from a study …

View Post

Time to Revisit Distant Nodal Status in Breast Cancer Curability?

In Clinical Studies News by Barbara Jacoby

By: Charles Bankhead, Senior Editor From: medpagetoday.com Comparable survival for distant and regional nodal involvement, when treated similarly Patients with breast cancer with distant lymph node metastases (DLNM) had similar survival to that of patients with regional node involvement and significantly better survival than those with non-DLNM distant spread, an analysis of 2,000 cases showed. Women with DLNM at diagnosis …

View Post

Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen

In Clinical Studies News by Barbara Jacoby

From: businesswire.com – Trial will evaluate the efficacy and safety of Novartis’ targeted therapy TABRECTA® and Puma’s NERLYNX® in patients with metastatic HER2-negative breast cancer selected by Celcuity’s CELsignia Multi-Pathway Activity Test – This is Celcuity’s second clinical trial to treat patients diagnosed with hyperactive HER2 and c-Met signaling breast cancers with matching targeted therapies – Five clinical trial collaborations …

View Post

Adjuvant Hormonal Therapy Adherence Low Among Commercially Insured Patients With Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Janelle Bradley From: .journalofclinicalpathways.com Adjuvant hormonal therapy adherence at 5 years are low among commercially insured patients with breast cancer, according to a recent study (JCO Oncol Pract. 2021;OP2000248. doi:10.1200/OP.20.00248). “Tamoxifen and aromatase inhibitors are used as adjuvant hormonal therapy for early-stage hormone receptor-positive (HR+) breast cancer,” wrote Hui Zhao, PhD, Department of Health Services Research, The University of …

View Post

New study sheds light on cancer metastasis

In Clinical Studies News by Barbara Jacoby

Source: University of Colorado Anschutz Medical Campus From: news-medical.net Breast cancer is harmful enough on its own, but when cancer cells start to metastasize — or spread into the body from their original location — the disease becomes even more fatal and difficult to treat. Thanks to new research published in Oncogene from the lab of University of Colorado Cancer …

View Post

BDC-1001 +/- Immune Checkpoint Inhibitor Therapy Under Investigation for HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Sara Karlovitch From: targetedonc.com Currently, the only immune-based therapy for patients with HER2-driven or expressing cancers are anti-HER2 monoclonal antibodies. More treatment options are needed for patients who develop progressive disease. A trail in progress presented at the virtual 2020 San Antonio Breast Cancer Symposium suggests that immunostimulatory adjuvants such as toll-like receptor (TLR) 7/8 can help cause T-cells …

View Post

Are New Ways to Reduce Positive Margins in Breast Cancer Hope or Hype?

In Clinical Studies News by Barbara Jacoby

By: Anees B. Chagpar, MD, FACS From: onclive.com There are a number of strategies to reduce margin positivity, particularly after partial mastectomy, but the relative effectiveness of each varies, as do the data that support their use. Every breast cancer surgeon’s nemesis is the positive margin. A worthy adversary, positive margins are often elusive to intraoperative detection, and frequently require …

View Post

CONTESSA Trial Yields Positive Results for Patients with HER2-Positive Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Sara Karlovitch From: targetedonc.com In an interview with Targeted Oncology, Joyce O’Shaughnessy, MD, chair of Breast Cancer Research and chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center of Texas Oncology, discussed the CONTESSA study of tesetaxel with a reduced dose of capecitabine versus capecitabine alone in patients with HR-positive, HER2-negative breast cancer. New data suggests that a …

View Post

Changes detected in BRCA1 breast cells before they turn cancerous

In Clinical Studies News by Barbara Jacoby

From: cancerresearchuk.org A new study funded by Cancer Research UK has mapped out some of the earliest changes that occur in seemingly healthy breast tissue long before any tumours appear, which could have significant implications for the early detection of breast cancer. The paper, published today in Nature Communications(link is external), has discovered that before becoming cancerous, breast cells with the BRCA1 …

View Post

Considering Lymphedema Is Key for Multimodality Therapy of Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Audrey Sternberg From: cancernetwork.com Susan B. Kesmodel, MD, FACS, of the University of Miami, describes 3 methods by which breast surgical oncologists can strategize to reduce the incidence of lymphedema in patients undergoing surgery for breast tumors. When considering management of the axilla in patients undergoing surgical procedures for breast cancer, it is important to consider lymphedema, particularly when …